Vitamin K2 for Health & Longevity

Evidence Review created on 09/09/2026 using AI4L / Opus 5

Also known as: Menaquinone, Menaquinones, Menatetrenone, Menaquinone-4, Menaquinone-7, MK-4, MK-7

Motivation

Vitamin K2 (menaquinone) is one of the two natural families of vitamin K. Unlike vitamin K1, which comes from leafy greens and is used mostly by the liver, K2 comes from fermented foods, a few animal products, and gut bacteria, and it reaches tissues beyond the liver. There it switches on proteins that decide where calcium ends up — bound into bone, or deposited in the walls of arteries.

Interest grew from two directions. In Japan, a high-dose form has been an approved bone medicine for decades. In Europe, long-running population studies reported that people eating the most K2 had less hardened arteries and fewer heart deaths. Fermented soybean dishes, unusually rich in the long-lasting form, are common where several of those observations were first made. Supplement use has since spread far beyond either setting.

This review examines what controlled trials and population data show about vitamin K2 for bone, blood vessel, and blood sugar outcomes, how the two main supplement forms differ, where the evidence conflicts, and what the risks and drug interactions are.

Benefits - Risks - Protocol - Conclusion

Recommended Reading

This section collects high-level overviews of vitamin K2 from expert platforms and the academic literature.

• Differences between vitamin K1 and K2 - Rhonda Patrick

  A short video clip that separates the plant form from the bacterial form, explains why humans convert one to the other poorly, and sets up the calcium-routing argument used throughout this review.

• Vitamin K2: What It Does, Its Benefits, & Where to Find It - Chris Kresser

  A practitioner-facing overview of food sources, the K1-to-K2 conversion problem, and dosing. Kresser sells a supplement line, so the framing favours supplementation; the food-source tables remain the useful part.

• Vitamin K and Your Heart - Nancy Pearlson

  A current, heavily referenced summary of the cardiovascular literature with the underlying cohort and trial citations listed. Life Extension manufactures and sells vitamin K2 products, so the selection is favourable.

• Vitamin K2 Uses and Possible Side Effects - Stephen Rose

  A longevity-oriented overview from a non-commercial research nonprofit, covering absorption, retention, and the less-discussed immune, endocrine, and gut effects alongside the bone and vessel material.

• The role of menaquinones (vitamin K2) in human health - Beulens et al., 2013

  The narrative review that framed the case for treating menaquinones separately from K1 when setting intake recommendations, and that catalogues what is still unknown about their metabolism.

Content from two priority experts could not be found. A site search of peterattiamd.com for “vitamin K2” returned “Nothing Found”, and a search of hubermanlab.com returned no matching episodes or articles; neither platform appears to carry material that discusses vitamin K2 in substantial depth.

Grokipedia

• Vitamin K2

  The dedicated encyclopedia entry covering the menaquinone series, the carboxylation mechanism, dietary sources, and the bone and vascular literature in one place.

Examine

• Vitamin K

  Examine’s primary page for the nutrient, grading outcomes across 18 trials and 12 meta-analyses, with separate dose ranges for MK-4 and MK-7 (the short- and long-acting menaquinone forms).

ConsumerLab

• Vitamin K Supplements Review (Including Calcium, Vitamin D, Magnesium & Boron)

  Independent laboratory testing of marketed vitamin K products, with top picks, label-accuracy findings, and coverage of the forms, doses and drug interactions that matter when buying. Most detail sits behind a paid membership.

Systematic Reviews

The following systematic reviews and meta-analyses cover the principal claimed benefits of vitamin K2 and its principal risk.

• Efficacy of vitamin K2 in the prevention and treatment of postmenopausal osteoporosis: A systematic review and meta-analysis of randomized controlled trials - Ma et al., 2022

  Sixteen randomized controlled trials (studies in which participants are assigned by chance to treatment or control) and 6,425 women; the largest current bone-specific pooling.

• Vitamin K for the primary prevention of cardiovascular disease - Hartley et al., 2015

  The Cochrane review on the cardiovascular claim; it found only one eligible 60-person trial, which is itself the key finding.

• Vitamin K Supplementation for the Prevention of Cardiovascular Disease: Where Is the Evidence? A Systematic Review of Controlled Trials - Vlasschaert et al., 2020

  Nine controlled trials of arterial calcification, atherosclerosis, and stiffness; concludes the calcification benefit is inconsistent despite reliable marker changes.

• Vitamin K supplementation impact in dialysis patients: a systematic review and meta-analysis of randomized trials - Andrian et al., 2023

  Eleven trials and 830 dialysis patients, the population with the most severe functional vitamin K deficit and the most calcification to reverse.

• Interaction Between Dietary Vitamin K Intake and Anticoagulation by Vitamin K Antagonists: Is It Really True?: A Systematic Review - Violi et al., 2016

  Eleven studies on the principal risk of vitamin K intake — loss of anticoagulant control — and the intake threshold above which it becomes detectable.

Mechanism of Action

Vitamin K2 acts as an enzyme cofactor, not a hormone. Gamma-glutamyl carboxylase (GGCX, the enzyme that attaches carboxyl groups to specific proteins) uses the reduced vitamin to convert glutamate residues into gamma-carboxyglutamate. Only proteins carrying those residues bind calcium. A second enzyme, vitamin K epoxide reductase (VKOR, which regenerates the vitamin after each reaction), recycles it, so small amounts sustain many reactions — and vitamin K antagonist drugs, which block VKOR, shut the system down.

Two of these proteins carry the longevity argument. Matrix Gla protein (MGP, a calcification inhibitor produced in artery walls and cartilage) coats calcium-phosphate crystals, blocking mineral deposition in vessels; mice lacking it die young of arterial calcification. Osteocalcin, made by bone-forming cells, binds calcium into the bone matrix.

Pharmacologically the two supplement forms differ. MK-4 has a half-life of roughly one to two hours and, at nutritional doses, does not raise serum levels; MK-7 has a half-life near three days, reaches tissues outside the liver, and accumulates with daily dosing (Sato et al., 2012, a manufacturer-funded comparison). Selectivity is narrow: it acts only as the carboxylase cofactor, binding no receptor. Both are cleared by CYP4F2 (a liver enzyme that breaks down vitamin K) via side-chain oxidation to metabolites excreted in bile and urine.

A competing reading holds that the status marker tracks intake rather than driving calcification, so correcting it need not change plaque behaviour — the reading favoured by trials that moved the marker without moving calcium scores (Vlasschaert et al., 2020).

Historical Context & Evolution

Vitamin K was identified in 1929 as the factor whose absence caused bleeding in chicks, and its original and still-undisputed use is the prevention of haemorrhage — including the injection given to newborns. Menaquinones were characterised later as the bacterial branch of the family, initially treated as a nutritional curiosity because the liver’s clotting requirement is met easily by K1.

Two findings redirected attention. In 1995 Japan licensed menatetrenone (MK-4) at 45 mg daily as an osteoporosis treatment, on the strength of trials showing preserved lumbar bone density and fewer fractures (Shiraki et al., 2000). In 1997 mice bred without matrix Gla protein were shown to die within weeks from calcified, ruptured arteries (Luo et al., 1997), which moved the vitamin from a clotting story to a calcium-routing story. The Rotterdam Study then reported that people in the highest third of menaquinone intake had less severe aortic calcification and lower coronary heart disease mortality (Geleijnse et al., 2004). A 2011 popular book on the “calcium paradox” carried the idea into consumer supplementation.

Scientific opinion has since split rather than converged, and remains open. Pooled Japanese fracture trials showed large reductions, while broader poolings including Western trials did not (Ma et al., 2022). Dose, chemical form, baseline dietary intake, and population differ across those trials, and no study has yet isolated which of them accounts for the divergence.

Expected Benefits

High 🟩 🟩 🟩

Slowed Loss of Bone Mineral Density

Vitamin K2 carboxylates osteocalcin, letting it bind calcium into bone. Three years of MK-7 at 180 µg daily slowed the age-related decline in bone density at the lumbar spine and femoral neck in 244 healthy postmenopausal women (Knapen et al., 2013). A pooling of 16 randomized trials in 6,425 women confirmed the lumbar spine effect (Ma et al., 2022), as did a meta-analysis in middle-aged and older adults (Xie et al., 2024). The Knapen trial came from manufacturer-linked VitaK. The effect is site-specific: total hip density did not change.

Magnitude: Pooled mean difference of 1.02 percentage points in lumbar spine bone mineral density change versus control across 10 trials (P = 0.006); in the three-year MK-7 trial the treated group lost measurably less density at spine and femoral neck than placebo, with no change at the total hip.

Improved Glycaemic Control in Type 2 Diabetes ⚠️ Conflicted

MK-7 appears to improve insulin signalling, possibly via carboxylated osteocalcin and gut bacterial metabolites. In 68 adults with type 2 diabetes, 360 µg daily for 12 weeks lowered fasting glucose and HbA1c (glycated haemoglobin, average blood sugar over three months) versus placebo (Rahimi Sakak et al., 2021). A meta-analysis of six trials found consistent falls in HbA1c and insulin resistance (Nikpayam et al., 2025). Heterogeneity was very high; none ran past six months. Net reading: the direction reproduces, the size does not.

Magnitude: Pooled standardized mean difference (a unitless measure of effect size) of −0.32 for HbA1c and −0.56 for insulin resistance across six trials; the single largest trial reported an effect size of −0.36 for HbA1c over 12 weeks.

Reduced Fracture Incidence ⚠️ Conflicted

High-dose MK-4 is a licensed osteoporosis drug in Japan. A meta-analysis of seven Japanese randomized trials found large reductions in vertebral, hip, and non-vertebral fractures (Cockayne et al., 2006), and a 24-month trial in 241 patients found fewer fractures on 45 mg daily (Shiraki et al., 2000). Broader pooling with non-Japanese trials found no overall effect until one heterogeneous study was removed (Ma et al., 2022). Dose, form, and diet differ between the two literatures. Net reading: established for high-dose MK-4 in Japanese cohorts, unconfirmed elsewhere.

Magnitude: Odds ratios (the ratio of the odds of an event between groups) of 0.40 for vertebral, 0.23 for hip, and 0.19 for all non-vertebral fractures in the Japanese pooling; relative risk (the ratio of event rates between groups) 0.96 in the broader pooling, falling to 0.43 after one outlier trial was excluded.

Medium 🟩 🟩

Reduced Arterial Stiffness in Postmenopausal Women

Carboxylated matrix Gla protein inhibits mineral deposition in the arterial wall, and stiffness is the functional consequence. Three years of MK-7 at 180 µg daily reduced carotid-femoral pulse wave velocity (the speed a pressure wave travels along the aorta) in 244 healthy postmenopausal women, most in those stiffest at baseline (Knapen et al., 2015). A one-year trial in 165 women reproduced the direction (de Vries et al., 2025). Both were manufacturer-funded. In chronic kidney disease a 159-person trial found no benefit (Witham et al., 2020).

Magnitude: Pulse wave velocity and the stiffness index fell significantly over three years in the treated group, with distensibility and compliance (how much the artery widens under pressure, and how easily it does so) improving only in women whose baseline stiffness index exceeded the cohort median of 10.8; the one-year trial reported roughly a 3% fall in brachial blood pressure in the stiffest subgroup.

Lower Cardiovascular Mortality with Higher Dietary Menaquinone Intake

Multiple large prospective cohorts point the same way. In 4,807 adults over 10 years, the highest third of menaquinone intake had lower coronary heart disease mortality, lower all-cause mortality, and less severe aortic calcification, while K1 showed nothing (Geleijnse et al., 2004). In 53,372 Danes followed 21 years, the highest K2 intake carried fewer atherosclerotic hospitalisations (Bellinge et al., 2021). A 33,289-person Dutch cohort found no all-cause mortality association (Zwakenberg et al., 2017). Dietary K2 travels with cheese, eggs, and fermented foods that confounding cannot separate.

Magnitude: Relative risk 0.43 for coronary heart disease mortality and 0.74 for all-cause mortality in the top intake third; hazard ratio (the ratio of event rates over time) 0.86 for atherosclerotic hospitalisation in the Danish cohort; hazard ratio 0.86 per 10 µg daily for coronary mortality in the null Dutch cohort.

Reduced Frequency and Severity of Nocturnal Leg Cramps

Menaquinone may act on muscle calcium handling and neuromuscular excitability, though the mechanism is unproven. In 199 community-dwelling adults aged 65 and over, MK-7 at 180 µg daily for eight weeks cut the weekly frequency, duration, and severity of night-time leg cramps against placebo (Tan et al., 2024). The journal retracted and replaced the paper in 2025 after data corrections, and the corrected result stands. It remains a single trial, run in one country, with no independent replication.

Magnitude: Weekly cramp frequency fell from 2.60 to 0.96 episodes on MK-7 while rising from 2.71 to 3.63 on placebo, a between-group difference of −2.67 episodes per week; cramp severity fell 2.55 points versus 1.24 on a 10-point scale.

Low 🟩

Slowed Coronary Artery Calcification ⚠️ Conflicted

Two years of MK-7 at 360 µg daily slowed calcium score progression in 167 symptomatic coronary patients (Vossen et al., 2026). A larger aortic valve trial (Diederichsen et al., 2022) and a smaller diabetes trial (Zwakenberg et al., 2019) found none. Net reading: possibly real in calcified plaque, unsupported elsewhere.

Magnitude: Median coronary calcium score rose from 145 to 214 Agatston units on placebo versus 135 to 184 on MK-7 over two years (P = 0.02); the aortic valve trial found a 17 Agatston unit difference, not significant.

Reduced Liver Cancer Recurrence and Mortality ⚠️ Conflicted

Pooling 11 studies and 1,030 patients treated for liver cancer found lower recurrence and mortality at one, two, and three years (de Moraes et al., 2026). An earlier pooling of five trials found no survival benefit (Riaz et al., 2012). Net reading: promising but unreplicated.

Magnitude: Odds ratio 0.41 for three-year recurrence and 0.37 for three-year mortality in the newer pooling; relative risk 0.71 for three-year recurrence and no overall survival effect in the earlier one.

Speculative 🟨

Increased Testosterone Production

Rats fed MK-4 for five weeks had higher plasma and testicular testosterone, and testis-derived cells raised output dose-dependently (Ito et al., 2011). No human trial exists; the basis is animal and cell work only.

Improved Carboxylation of Extra-Hepatic Vitamin K Proteins

Supplementation reliably lowers dephosphorylated-uncarboxylated matrix Gla protein and undercarboxylated osteocalcin in nearly every trial that measures them, including null ones (Vlasschaert et al., 2020). These markers are not validated surrogates for any human outcome.

Benefit-Modifying Factors

• Vitamin K cycle gene variants: Variants in VKORC1 (the gene for the recycling enzyme) and GGCX (the gene for the carboxylating enzyme) change how much vitamin K a given protein pool needs, so low-activity carriers may require higher intakes.

• Apolipoprotein E genotype: APOE (a gene governing how fat-carrying particles are cleared from blood) determines how fast vitamin K-bearing lipoproteins are removed by the liver. E4 carriers clear them fastest, which may leave less menaquinone available to bone and arterial tissue.

• Baseline vitamin K status: Benefit scales with starting deficit. Trials enrolling participants selected for low vitamin K status or elevated dephosphorylated-uncarboxylated matrix Gla protein produced larger changes than trials in replete participants (de Vries et al., 2025).

• Baseline arterial stiffness: In the three-year stiffness trial, improvements in distensibility, compliance, and local pulse wave velocity appeared only in women whose baseline stiffness index sat above the cohort median (Knapen et al., 2015).

• Sex: Almost every positive bone and vascular trial enrolled postmenopausal women. The largest male-only trial, in men averaging 71 years with heavy aortic valve calcification, was null (Diederichsen et al., 2022), so the benefit profile in men is largely unestablished.

• Pre-existing conditions: Dialysis, chronic kidney disease, and type 2 diabetes all produce marked functional vitamin K deficiency, which raises the theoretical headroom for benefit — yet controlled trials in these groups have generally failed to shift calcification scores (Andrian et al., 2023).

• Age and menopausal stage: Bone and vascular effects were demonstrated in adults in their fifties through seventies. In pre- and perimenopausal women the same one-year protocol moved the status marker but not vascular stiffness, suggesting little to correct before bone loss accelerates.

• Dietary fat at the time of intake: Menaquinones are fat-soluble and are absorbed inside mixed micelles (droplets that bile forms around dietary fat). Absorption is higher when the dose is taken with a fat-containing meal, so fasted dosing reduces the delivered amount.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Loss of Anticoagulant Control on Vitamin K Antagonists

Warfarin, acenocoumarol, and phenprocoumon work by blocking vitamin K recycling, so supplemental menaquinone directly reverses the intended drug effect. In anticoagulated healthy volunteers held at a target INR (international normalized ratio, the standardised measure of clotting time) of 2.0, stepped MK-7 doses progressively restored clotting factor activity and thrombin generation (Theuwissen et al., 2013). A systematic review of 11 studies confirmed the interaction becomes detectable above roughly 150 µg of daily vitamin K intake (Violi et al., 2016). The consequence is under-anticoagulation and thromboembolism (a clot blocking a vessel).

Magnitude: 45 µg of MK-7 daily — below a single common capsule — lowered mean INR and uncarboxylated factor II by about 40%; 10 µg and 20 µg produced clinically relevant INR falls in 40% and 60% of subjects respectively, and raised thrombin generation by about 20% and 30%.

Medium 🟥 🟥

Gastrointestinal Symptoms

Nausea, abdominal pain, and diarrhoea are the adverse events most often recorded in vitamin K trials and are listed as the common side effects in Examine’s clinician safety database. They are dose-related, transient, and reduced by taking the dose with food. Pooled adverse-reaction rates across 16 randomized trials were indistinguishable from control, so these symptoms occur but do not clearly exceed background (Ma et al., 2022).

Magnitude: Pooled relative risk for any adverse reaction 1.03 (95% confidence interval — the range within which the true value probably lies — 0.87 to 1.21) across 16 trials, meaning no detectable excess over control.

Small Rise in Serum Calcium in Dialysis Populations

Pooled randomized data in dialysis patients showed a modest but statistically significant increase in serum calcium on vitamin K supplementation, alongside the expected fall in the calcification marker (Andrian et al., 2023). In a population already managed for calcium-phosphate balance this direction is unwanted. The review’s authors flagged bias concerns across the included trials, and no equivalent signal has been reported in participants with normal kidney function.

Magnitude: Pooled mean difference of 0.18 (95% confidence interval 0.04 to 0.32) in serum calcium across 11 trials and 830 dialysis patients; the clinical significance of a shift of this size has not been established.

Low 🟥

Hypersensitivity to Fermentation-Derived Preparations

Most commercial MK-7 is produced by bacterial fermentation of soybeans. Late-onset anaphylaxis to natto, confirmed by provocation testing and attributed to poly-gamma-glutamic acid rather than to soy protein, is documented in case series (Inomata et al., 2007). Reactions to purified supplements are not established.

Magnitude: Not quantified in available studies. Only case reports and small case series exist; no controlled trial has measured hypersensitivity incidence for fermentation-derived menaquinone supplements.

Speculative 🟨

Increased Active Calcification Signal on Molecular Imaging ⚠️ Conflicted

In 60 patients with diabetes and cardiovascular disease, MK-7 borderline raised femoral sodium fluoride uptake, an unvalidated imaging biomarker (Zwakenberg et al., 2019). Conventional imaging showed nothing. Net reading: probably an artefact.

Thrombosis from Enhanced Clotting Factor Carboxylation

Vitamin K activates clotting factors, so high intakes might promote thrombosis. A one-year trial at 360 µg daily in 123 dialysis patients found none (Bladbjerg et al., 2024). The concern remains mechanistic.

Risk-Modifying Factors

• Warfarin sensitivity gene variants: VKORC1 and CYP2C9 (a liver enzyme gene that clears warfarin) variants determine the anticoagulant dose needed. Carriers on low doses have the least margin, so a fixed menaquinone intake shifts their INR proportionally more.

• Baseline INR and anticoagulant regimen: The interaction scales with how tightly clotting is suppressed. Someone held at an INR of 2.5 to 3.5 for a mechanical valve loses control at lower menaquinone intakes than someone targeting 2.0 to 3.0.

• Baseline serum calcium and phosphate: In dialysis and advanced kidney disease, calcium sits near the top of its managed range already, so the small pooled rise on supplementation matters more than the same shift would in normal kidney function.

• Sex: No sex-specific adverse-event signal is reported. Safety data come from trials in postmenopausal women; the largest male cohort, 365 men on 720 µg MK-7 for two years, recorded no excess deaths or cardiovascular events (Diederichsen et al., 2022).

• Pre-existing conditions: Cholestatic liver disease (reduced bile flow), Child-Pugh Class C cirrhosis, cystic fibrosis, coeliac disease, and short bowel syndrome all impair fat-soluble vitamin absorption, making both the delivered dose and its clotting effect unpredictable.

• Age and polypharmacy: Adults over 70 carry the highest prevalence of anticoagulant, bile acid sequestrant, and lipid-blocking drug use simultaneously, which multiplies the chance that a menaquinone supplement collides with an existing prescription.

Key Interactions & Contraindications

• Vitamin K antagonists (warfarin, acenocoumarol, phenprocoumon): Absolute contraindication without physician supervision. Direct pharmacological opposition; consequence is under-anticoagulation, stroke, or thromboembolism. Doses as low as 10 µg daily shift INR. Mitigation: avoidance of the combination, or fixed intake with weekly INR monitoring through any change.

• Direct oral anticoagulants (apixaban, rivaroxaban, edoxaban, dabigatran): No interaction. These block factor Xa or thrombin directly and do not depend on vitamin K recycling, so menaquinone does not oppose them. Severity: none. This is the standard route for anticoagulated patients needing vitamin K.

• Bile acid sequestrants (cholestyramine, colestipol, colesevelam): Caution. They bind bile acids and block micelle formation, reducing menaquinone absorption and lowering the delivered dose. Mitigation: administration separated by at least four hours, with vitamin K status monitoring in long-term use.

• Fat absorption blockers (orlistat, mineral oil): Caution. Reduced fat absorption lowers uptake of all fat-soluble vitamins including K. Mitigation: the menaquinone dose separated from orlistat by at least two hours, per the manufacturer’s fat-soluble vitamin guidance.

• Broad-spectrum antibiotics (cefoperazone, cefotetan, rifampin, prolonged courses of any class): Caution. They suppress menaquinone-producing gut bacteria and, for the cephalosporins carrying an N-methylthiotetrazole side chain, additionally inhibit vitamin K recycling. Consequence: bleeding risk, not reduced supplement effect.

• High-dose vitamin E (above roughly 800 IU, or international units, daily): Caution. Tocopherol metabolites antagonise vitamin K-dependent carboxylation and can prolong clotting time. Mitigation: avoidance of sustained high-dose vitamin E alongside anticoagulants; no dose adjustment is needed for menaquinone itself.

• Vitamin D and calcium supplements: Additive by design, not adverse. Vitamin D increases synthesis of osteocalcin and matrix Gla protein; menaquinone activates them. Most trials in this review co-administered vitamin D. Severity: serum calcium monitoring where combined doses are high.

• Statins (atorvastatin, rosuvastatin, simvastatin): Theoretical caution. These cholesterol-lowering drugs suppress the lipid pathway supplying the side chain that converts vitamin K1 to MK-4 in tissue, which may lower the body’s own MK-4. No clinical outcome has been attributed to this; no dose change is indicated.

• Populations who should avoid Vitamin K2:

  • Anyone taking a vitamin K antagonist to any INR target of 2.0 or above, unless the anticoagulation clinic manages the combination explicitly
  • People with a documented late-onset anaphylactic reaction to natto or to poly-gamma-glutamic acid, for fermentation-derived MK-7 specifically
  • People with Child-Pugh Class C cirrhosis or untreated cholestasis, in whom absorption and clotting effects are unpredictable
  • Newborns, for whom vitamin K prophylaxis is a defined clinical protocol that oral menaquinone supplements do not substitute for

Risk Mitigation Strategies

• Anticoagulant status established before starting: Establishes whether the single serious interaction applies. Anyone on warfarin, acenocoumarol, or phenprocoumon needs a switch to a direct oral anticoagulant or clinic supervision, because 10 µg daily already shifts INR.

• Fixed intake once started: Prevents the swing in clotting control that stopping or restarting produces. Abrupt discontinuation has raised INR into the bleeding range; a constant daily dose is safer than an intermittent one.

• Dosing with a fat-containing meal: Improves micelle-dependent absorption and reduces nausea, abdominal pain, and diarrhoea, the most commonly reported adverse events. A meal containing roughly 10 g of fat is sufficient.

• Starting dose of 90–100 µg MK-7 rather than 180–360 µg: Limits the size of any unrecognised interaction and gives room to observe tolerance. Doses in this range still lower the vitamin K status marker, though more slowly than higher doses.

• Serum calcium monitoring where kidney function is reduced: Addresses the small pooled calcium rise seen in dialysis populations. An albumin-corrected calcium at baseline and at three months detects the shift before it disturbs calcium-phosphate management.

• Non-natto-derived or synthetic MK-7 where allergen history exists: Removes exposure to poly-gamma-glutamic acid, the antigen behind documented late-onset anaphylaxis to fermented soybean products.

• Separation from bile acid sequestrants and orlistat: Preserves the delivered dose. A four-hour gap from cholestyramine or colestipol and a two-hour gap from orlistat prevents the absorption loss that otherwise makes the supplement inert.

Therapeutic Protocol

• Standard MK-7 protocol: 90–180 µg once daily with a fat-containing meal, continued indefinitely. This is the dose range used in the Dutch trials that reported bone density and arterial stiffness effects, and the range most commonly sold.

• Higher-dose MK-7 protocol: 360 µg once daily, used in the coronary calcification, diabetes, and dialysis trials. Reserved for established calcification or documented poor vitamin K status; it has no demonstrated advantage in healthy adults.

• Japanese high-dose MK-4 protocol: 45 mg daily, usually split as 15 mg three times with meals. This is the licensed osteoporosis regimen behind the Japanese fracture trials and is a pharmaceutical dose, not a nutritional one.

• Competing approach — food first: Some practitioners target 100–200 µg daily from natto, hard and soft cheeses, egg yolk, and goose liver instead of capsules, on the grounds that the cohort evidence is dietary rather than supplemental.

• Popularised by: The MK-7 protocols trace to Cees Vermeer’s VitaK group at Maastricht University; the 45 mg MK-4 regimen to Japanese bone clinics; the consumer food-first framing to Chris Kresser and to Kate Rhéaume-Bleue’s 2011 book.

• Half-life and dose splitting: MK-7 has a half-life near three days, so once-daily dosing gives stable levels and splitting is unnecessary. MK-4’s half-life is one to two hours, which is why its protocol requires three doses daily.

• Best time of day: Whenever the largest fat-containing meal falls, most often the evening meal. No circadian effect on carboxylation has been demonstrated; absorption, not timing, drives the choice.

• Genetic considerations: VKORC1 and GGCX low-activity variants raise the intake needed for a given carboxylation effect, and APOE4 carriers clear vitamin K faster. No dosing algorithm exists; these variants argue for the status marker over a fixed dose.

• Sex-based differences: No sex-specific dosing has been established. The 90–180 µg range was validated in postmenopausal women; the one large male trial used 720 µg with vitamin D and found no effect on its endpoint (Diederichsen et al., 2022).

• Age considerations: Functional vitamin K insufficiency rises steeply with age, so adults past 65 are the group most likely to have a deficit to correct. Below the age of menopause the same protocol moves markers without measurable vascular change.

• Baseline biomarker guidance: Where available, dephosphorylated-uncarboxylated matrix Gla protein above roughly 500 pmol/L identifies functional insufficiency and argues for the higher end of the range; a replete value argues for the lower end or for food alone.

• Pre-existing conditions: Chronic kidney disease, dialysis, and type 2 diabetes carry the largest vitamin K deficits and were dosed at 360 µg in trials. Fat malabsorption states require higher intakes or monitoring, because the absorbed fraction is unpredictable.

Discontinuation & Cycling

• Intended duration: Lifelong rather than short-term. Vitamin K is stored poorly and turns over within days, so carboxylation status returns toward baseline within weeks of stopping; every positive trial ran continuously for one to three years.

• Withdrawal effects: None in people not taking anticoagulants. In those on a vitamin K antagonist, stopping a supplement removes the counter-pressure and allows the INR to rise sharply, which is a documented bleeding hazard rather than a withdrawal syndrome.

• Tapering: Not required for the supplement itself. Where a vitamin K antagonist is co-prescribed, anticoagulation clinics step any change up or down with INR checks, because the clotting effect appears within days of a dose change.

• Cycling: Not supported. No tolerance, receptor downregulation, or loss of effect over time has been reported; the three-year trials showed effects that grew rather than faded, so continuous dosing is the pattern with evidence behind it.

Sourcing and Quality

• Form matters more than dose: MK-7 raises serum levels at nutritional doses; MK-4 does not, and requires milligram quantities to register at all. A product listing “vitamin K2” without specifying the homologue is not interchangeable between the two.

• All-trans isomer content: Only the all-trans configuration of MK-7 is biologically active. Cheaper synthetic material can contain substantial cis isomer, which is inert. Reputable labels state all-trans content explicitly.

• Label accuracy: ConsumerLab reports that vitamin K products have been found to contain more or less than the labelled amount. Independent verification matters more here than for nutrients with a wide safety margin, given the anticoagulant interaction.

• Third-party testing: A current certificate of analysis and a seal from an independent programme such as United States Pharmacopeia, NSF International, or Informed Choice confirm identity, potency, and the absence of heavy metal and solvent residues.

• Source of the raw material: Fermentation-derived MK-7 from Bacillus subtilis natto carries the poly-gamma-glutamic acid antigen implicated in natto hypersensitivity. Synthetic all-trans MK-7 avoids it entirely and is the alternative where allergy is a concern.

• Named ingredient brands: MenaQ7 and K2VITAL are the two raw-material lines used in most of the trials cited in this review. Both are manufacturer-owned, and both companies have funded trials of their own material.

• Formulation and stability: Oil-suspended softgels protect MK-7 better than dry powder capsules, and MK-7 degrades when co-formulated with unchelated minerals such as calcium carbonate. Combination bone products are the least stable format.

Practical Considerations

• Time to effect: The vitamin K status marker halves within 8 to 12 weeks. Bone density and arterial stiffness changes took one to three years to separate from placebo, so nothing measurable happens on a scale of weeks.

• Common pitfall — wrong homologue: Buying an MK-4 product at a nutritional dose of 100–200 µg reproduces neither literature. That dose does not raise serum MK-4 at all; the Japanese evidence used 45 mg, roughly 300 times more.

• Common pitfall — fasted dosing: Taking the capsule on an empty stomach or with a fat-free breakfast substantially reduces absorption. This is the most likely reason a correctly chosen product produces no marker change.

• Common pitfall — unmanaged anticoagulation: Adding vitamin K2 while on warfarin without telling the anticoagulation clinic is the one genuinely dangerous error, and the risk runs in both directions — starting and stopping.

• Regulatory status: In the United States and European Union, vitamin K2 is a dietary supplement or food supplement, not a drug, so pre-market efficacy review does not apply. In Japan, menatetrenone at 45 mg is a licensed prescription osteoporosis medicine.

• Cost and accessibility: Neither expensive nor hard to obtain. MK-7 at 100–180 µg daily typically costs a few dollars a month, is sold without prescription in most markets, and is not reimbursed by any insurer.

• Payer incentives and the evidence gap: Menaquinone is unpatentable and costs cents daily, so insurers would save if it replaced reimbursed bone and lipid drugs — yet neither payers nor manufacturers fund the large outcome trials guidelines require. That gap is structural.

• Testing accessibility: The status marker used throughout the trial literature is a research assay rather than a routine clinical test, and is not offered by most commercial laboratories. Its practical unavailability is a real constraint on individualised dosing.

Interaction with Foundational Habits

• Sleep: No direct interaction in either direction. No trial has reported sleep disturbance, sedation, or altered sleep architecture with menaquinone at any dose, and no mechanism connects vitamin K-dependent carboxylation to circadian or sleep-regulating pathways. Timing relative to bedtime is therefore free, and the dose can sit with whichever meal is largest.

• Nutrition: Directly potentiating. Absorption depends on dietary fat, so the dose belongs with a meal containing fat rather than coffee or a fat-free breakfast. Fermented foods — natto, Gouda, Edam, sauerkraut — add menaquinones on top of the supplement, while very low-fat diets and fat-blocking agents blunt it. Vitamin D is complementary.

• Exercise: Indirect and favourable. Resistance and impact loading remain the dominant stimulus for bone density; menaquinone acts on the mineralisation step downstream, so the two address different parts of the same outcome. No blunting of hypertrophy or endurance adaptation is reported, and no timing relationship to training has been established.

• Stress management: No demonstrated interaction. Cortisol, the hypothalamic-pituitary-adrenal axis (the body’s stress hormone system), and the stress response are unaffected by menaquinone in humans. The indirect link runs the other way: chronic glucocorticoid exposure accelerates bone loss, the outcome menaquinone is used to slow, so stress reduction is complementary.

Monitoring Protocol & Defining Success

Before starting, the useful baseline is a clotting panel and a picture of calcium handling: prothrombin time with INR, albumin-corrected serum calcium, 25-hydroxyvitamin D, and kidney function. Where the intent is bone, a dual-energy X-ray absorptiometry scan sets the reference; where it is vascular, a coronary calcium score does. The vitamin K status marker is a research assay and is rarely obtainable, so most people will track intake and downstream outcomes instead.

Ongoing monitoring where a vitamin K antagonist is involved runs INR at one and four weeks, then at the clinic’s usual interval. Serum calcium and vitamin D are repeated at three months, then every six to twelve months. Bone density and calcium scoring change slowly and are not usefully repeated inside two years. Success at two to three years means slowed density loss or a calcium score rising more slowly than the untreated trajectory.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
INR (international normalized ratio)	1.0 if not anticoagulated; unchanged from the clinic target if anticoagulated	Detects the one serious interaction	Only relevant on a vitamin K antagonist; conventional labs report it without a functional range. Checked at 1 and 4 weeks after any change
Prothrombin time	11–13 seconds	Confirms clotting factor carboxylation is intact	Fasting not required. Pairs with INR; abnormal values point to malabsorption rather than to the supplement
Dephosphorylated-uncarboxylated matrix Gla protein (dp-ucMGP)	Below 300–500 pmol/L	The direct read-out of extra-hepatic vitamin K sufficiency	Research assay, rarely available commercially; conventional laboratories offer no reference range at all. Not a validated outcome surrogate
Undercarboxylated osteocalcin (ucOC) as a fraction of total osteocalcin	Below 20%	Bone-specific vitamin K sufficiency	Fasting sample preferred; osteocalcin has a diurnal peak overnight, so morning draws are used. Also a research assay
Serum calcium (albumin-corrected)	2.20–2.45 mmol/L (8.8–9.8 mg/dL)	Detects the small rise reported in kidney disease	Conventional range extends to 2.55 mmol/L. Albumin-corrected; paired with phosphate and parathyroid hormone where kidney function is reduced
25-hydroxyvitamin D	30–50 ng/mL (75–125 nmol/L)	Vitamin D drives synthesis of the proteins vitamin K2 activates	Conventional labs call 20 ng/mL sufficient. Best paired with the calcium panel and repeated seasonally
Estimated glomerular filtration rate (eGFR)	Above 60 mL/min/1.73 m²	Identifies who carries both the largest deficit and the calcium-rise risk	eGFR is a measure of how well the kidneys filter. Non-fasting. Below 45 mL/min/1.73 m², calcium is monitored more closely
Bone mineral density (DXA T-score)	Above −1.0	The endpoint the bone evidence is built on	DXA is dual-energy X-ray absorptiometry, a low-dose bone density scan. No established target for supplementation alone; change from the individual’s own baseline is what is tracked. Not usefully repeated inside 2 years
Coronary artery calcium score	0 Agatston units	The endpoint the vascular evidence is built on	No established on-treatment target; the annual rate of rise against the individual’s own baseline is what is tracked, rather than an absolute number
HbA1c (glycated haemoglobin)	Below 5.4%	Where the metabolic claim would show up	Non-fasting. Conventional threshold for prediabetes is 5.7%; paired with fasting insulin and repeated at 3 months

Qualitative markers are weak for this intervention and are not reliable indicators, but the following are tracked in practice:

• Unexplained bruising or bleeding at the gums, which points to over-anticoagulation rather than to the supplement
• Nausea, abdominal discomfort, or loose stools in the first weeks, which usually resolve when the dose moves to a fatty meal
• Dental calculus (hardened plaque on the teeth) and tooth sensitivity, occasionally reported anecdotally and without trial support
• Absence of any perceptible change, which is the expected experience and not evidence the protocol has failed

Emerging Research

• InterVitaminK trial: NCT05259046 randomises 450 Danish adults to MK-7 or placebo with total coronary artery calcification as the primary endpoint, plus metabolic and bone outcomes. Completion is scheduled for February 2027. It is the largest general-population trial running.

• Two-year coronary calcification result: The recently published VitaK-CAC trial is the first randomised evidence that MK-7 slows calcium score progression in symptomatic coronary disease. Whether slowing the score translates into plaque stability or fewer events is explicitly unresolved.

• Vitamin K2 in episodic migraine: NCT05943457 is recruiting 160 adults to test MK-7 against placebo on monthly migraine days and arterial stiffness. A positive result would open an entirely new indication; the mechanism proposed is vascular rather than neurological.

• Vitamin K and knee osteoarthritis: NCT06385275 at Boston University is a phase 1/2 trial in 49 participants tracking uncarboxylated matrix Gla protein and MK-7 levels, targeting cartilage mineralisation. A companion Tufts trial, NCT05505552, measures lower-extremity function.

• Vitamin K and cognition: NCT06855953, a 40-participant study at the Montreal Heart Institute, measures processing speed, executive function, and episodic memory in coronary heart disease. Vitamin K’s role in brain sphingolipid metabolism (the building of fat molecules in brain cell membranes) is the stated rationale and remains untested in humans.

• Evidence that could weaken the case: The aortic valve calcification trial (Diederichsen et al., 2022) in 365 men and the K4Kidneys trial (Witham et al., 2020) in 159 kidney patients both moved the status marker and changed nothing clinically. Further null trials would settle the marker-versus-outcome question against supplementation.

• The unresolved dose and form question: No trial has compared MK-4 and MK-7 head to head on a clinical endpoint. Until one does, the Japanese fracture literature and the Dutch vascular literature cannot be reconciled, and neither can be extrapolated to the other’s dose.

Conclusion

Vitamin K2 is a family of fat-soluble compounds that switch on proteins deciding where the body deposits calcium. Two supplement forms dominate: a short-acting one used at very high doses in Japanese bone medicine, and a long-acting one used at far smaller doses everywhere else. They are not interchangeable, and swapping the dose of one onto the other reproduces neither body of evidence.

The firmest human findings are that supplementation slows the loss of bone density at the spine after menopause and lowers average blood sugar in people with type 2 diabetes. Fracture prevention is supported by repeated trials in one country and not reproduced elsewhere, and the reasons — dose, form, background diet — remain unsettled. The arterial evidence is genuinely split: one long trial slowed calcium build-up in narrowed coronary arteries, while trials in heart valve and kidney disease found nothing, even though the status marker moved every time. Population studies linking higher intake to fewer heart events point consistently the same way but cannot separate the nutrient from the fermented and animal foods carrying it.

Harm at supplemental doses appears minimal outside one clear situation: it opposes older blood-thinning drugs at amounts far below a single capsule.

Much of the pivotal trial work, and the marker used to judge it, comes from groups funded by or spun out of vitamin K2 manufacturers, and several of the consumer sites summarising it also sell the product.

Top - Benefits - Risks - Protocol